METHOD OF TREATING PROSTATE CANCER USING A COMBINATION BASED ON ANDROGEN RECEPTOR MODULATOR
The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a...
Saved in:
Main Authors | , , , , |
---|---|
Format | Patent |
Language | English Russian |
Published |
29.04.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a male human patient comprising orally administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the male human patient in need of such treatment at a dose of 30 to 480 mg per day in combination with (a) abiraterone acetate and (b) prednisone.
Изобретение относится к способу лечения метастатического кастрационно-резистентного рака предстательной железы, неметастатического кастрационно-резистентного рака предстательной железы, метастатического кастрационно-чувствительного рака предстательной железы, неметастатического кастрационно-чувствительного рака предстательной железы или локализованного рака предстательной железы высокого риска у пациента-человека мужского пола, включающему пероральное введение соединения формулы (I) или его фармацевтически приемлемой соли пациенту-человеку мужского пола, нуждающемуся в таком лечении, в дозе от 30 до 480 мг в сутки в комбинации с (a) абиратерон ацетатом и (b) преднизоном. |
---|---|
AbstractList | The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or high-risk localized prostate cancer in a male human patient comprising orally administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof to the male human patient in need of such treatment at a dose of 30 to 480 mg per day in combination with (a) abiraterone acetate and (b) prednisone.
Изобретение относится к способу лечения метастатического кастрационно-резистентного рака предстательной железы, неметастатического кастрационно-резистентного рака предстательной железы, метастатического кастрационно-чувствительного рака предстательной железы, неметастатического кастрационно-чувствительного рака предстательной железы или локализованного рака предстательной железы высокого риска у пациента-человека мужского пола, включающему пероральное введение соединения формулы (I) или его фармацевтически приемлемой соли пациенту-человеку мужского пола, нуждающемуся в таком лечении, в дозе от 30 до 480 мг в сутки в комбинации с (a) абиратерон ацетатом и (b) преднизоном. |
Author | HERBERT, Mark R SMITH, Nicholas D CHEN, Isan MANEVAL, Edna Chow HAGER, Jeffrey H |
Author_xml | – fullname: HERBERT, Mark R – fullname: SMITH, Nicholas D – fullname: HAGER, Jeffrey H – fullname: CHEN, Isan – fullname: MANEVAL, Edna Chow |
BookMark | eNqFi0sKg0AQBWeRLPI7Q_oCgRjxAO3YfiB2y9iuXIiEySqMgrk_MZB9Vq8o6u3NJkzB70xfk5aSgeSgjlArLqBx0ioqgUW25KBrvxbBSp1WvDbCkGJL64sBOXNSEIMjS42Kg1qy7o4rHc32Ob4Wf_rtwZxzUlte_DwNfpnHhw_-PRBe4yS6JWkU_y8-5qcyuw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | СПОСОБ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ НА ОСНОВЕ МОДУЛЯТОРА АНДРОГЕННОГО РЕЦЕПТОРА |
ExternalDocumentID | EA035125B1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_EA035125B13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:19:49 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English Russian |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_EA035125B13 |
Notes | Application Number: EA20150091340 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200429&DB=EPODOC&CC=EA&NR=035125B1 |
ParticipantIDs | epo_espacenet_EA035125B1 |
PublicationCentury | 2000 |
PublicationDate | 20200429 |
PublicationDateYYYYMMDD | 2020-04-29 |
PublicationDate_xml | – month: 04 year: 2020 text: 20200429 day: 29 |
PublicationDecade | 2020 |
PublicationYear | 2020 |
RelatedCompanies | ARAGON PHARMACEUTICALS, INC |
RelatedCompanies_xml | – name: ARAGON PHARMACEUTICALS, INC |
Score | 3.2546408 |
Snippet | The present invention relates to a method of treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer,... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | METHOD OF TREATING PROSTATE CANCER USING A COMBINATION BASED ON ANDROGEN RECEPTOR MODULATOR |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200429&DB=EPODOC&locale=&CC=EA&NR=035125B1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NT8IwFG8IGvWmqMHvHsxui2y0kB0W07UdYNy6jGJIPBC2QvQyCIz479tOUC_cmjZ9aV_yvvr6fg-ARzTFqOMoz3bnGbKR185sT7WUjXKlve1uF09bpnY4ijv9EXoZ43ENfOxqYSqc0K8KHFFLVK7lvaz09fLvEYtVfyvXT9mnnlo8h9Jn1jY6div9arHA54lgglqU-pxYceqbhJmLAx0nHRgn2qDs87fA1KQs_xuU8BQcJppWUZ6B2mrTAMd013etAY6ibbpbD7eStz4H7xGXfcGgCKFMOZGDuAeTVAwlkRxS02EmhaaFRg8SSEUUDH5gbmFAhlzviiGJWSp6PIYppzyRIoWRYKNXokcX4CHkkvZtfcrJL0MmnOyu074E9WJRzJoAdpCT47nS7ojjIcdTmQ7s8kzhfO7g3FHTK9DcR-V6_9INODFsNfkT17sF9XK1md1pM1xm9xUHvwEdG4TM |
link.rule.ids | 230,309,786,891,25594,76906 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NT8IwFG8IGvGmqMFPejC7LbLRQXZYTNd2DGXrMooh8UDYCtELEBjx37edoF64NW360r7kffX1_R4Aj2jqoI4lXdOeZ8hEbjszXdmSJsql8ra7XWfa0rXDUdwJR-hl7Iwr4GNfC1PihH6V4IhKonIl70Wpr1d_j1i0_Fu5eco-1dTyORAeNXbRsV3qV4P6Hks45cQgxGPYiFNPJ8xsx1dx0lFXY_Nqx-nN1zUpq_8GJTgDx4mitSjOQWW9rYMa2fddq4OTaJfuVsOd5G0uwHvERMgp5AEUKcOiH_dgkvKhwIJBojvMpFC30OhBDAmP_P4PzC308ZCpXTHEMU15j8UwZYQlgqcw4nQ0wGp0CZoBEyQ01SknvwyZMLy_TvsKVBfLxawBYAdZuTOXyh2xXGS5MlOBXZ5JJ59bTm7J6TVoHKJyc3ipCWqhiAaTQT9-vQWnmsU6l2K7d6BarLeze2WSi-yh5OY3e7yHuQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=METHOD+OF+TREATING+PROSTATE+CANCER+USING+A+COMBINATION+BASED+ON+ANDROGEN+RECEPTOR+MODULATOR&rft.inventor=HERBERT%2C+Mark+R&rft.inventor=SMITH%2C+Nicholas+D&rft.inventor=HAGER%2C+Jeffrey+H&rft.inventor=CHEN%2C+Isan&rft.inventor=MANEVAL%2C+Edna+Chow&rft.date=2020-04-29&rft.externalDBID=B1&rft.externalDocID=EA035125B1 |